Similar articles for PMID: 23729643

Year	Number of Results
1995	1
1998	2
1999	2
2000	2
2001	1
2002	1
2003	4
2004	3
2005	3
2006	4
2007	4
2008	9
2009	6
2010	10
2011	6
2012	11
2013	8
2014	4
2015	9
2016	4
2017	3
2018	6
2019	2
2020	6
2021	1
2024	0

1

Opioid pharmacogenetics of alcohol addiction.

Berrettini W. Berrettini W. Cold Spring Harb Perspect Med. 2013 Jul 1;3(7):a012203. doi: 10.1101/cshperspect.a012203. Cold Spring Harb Perspect Med. 2013. PMID: 23729643 Free PMC article. Review.

2

Alcohol addiction and the mu-opioid receptor.

Berrettini W. Berrettini W. Prog Neuropsychopharmacol Biol Psychiatry. 2016 Feb 4;65:228-33. doi: 10.1016/j.pnpbp.2015.07.011. Epub 2015 Jul 29. Prog Neuropsychopharmacol Biol Psychiatry. 2016. PMID: 26226591 Review.

3

Opioid neuroscience for addiction medicine: From animal models to FDA approval for alcohol addiction.

Berrettini W. Berrettini W. Prog Brain Res. 2016;223:253-67. doi: 10.1016/bs.pbr.2015.07.030. Epub 2015 Oct 21. Prog Brain Res. 2016. PMID: 26806780 Review.

4

The μ-opioid receptor and treatment response to naltrexone.

Thorsell A. Thorsell A. Alcohol Alcohol. 2013 Jul-Aug;48(4):402-8. doi: 10.1093/alcalc/agt030. Epub 2013 Mar 29. Alcohol Alcohol. 2013. PMID: 23543091 Review.

5

Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone.

Setiawan E, Pihl RO, Benkelfat C, Leyton M. Setiawan E, et al. Pharmacogenomics. 2012 Jul;13(10):1161-72. doi: 10.2217/pgs.12.99. Pharmacogenomics. 2012. PMID: 22909206 Review.

6

Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder.

Hartwell EE, Feinn R, Morris PE, Gelernter J, Krystal J, Arias AJ, Hoffman M, Petrakis I, Gueorguieva R, Schacht JP, Oslin D, Anton RF, Kranzler HR. Hartwell EE, et al. Addiction. 2020 Aug;115(8):1426-1437. doi: 10.1111/add.14975. Epub 2020 Feb 11. Addiction. 2020. PMID: 31961981 Free PMC article.

7

Preserved DNA from past clinical trials yields new information about a subtype of alcoholism.

O'Brien CP. O'Brien CP. Curr Psychiatry Rep. 2008 Oct;10(5):375-6. doi: 10.1007/s11920-008-0060-z. Curr Psychiatry Rep. 2008. PMID: 18803909 No abstract available.

8

Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.

Ray LA, Hutchison KE. Ray LA, et al. Arch Gen Psychiatry. 2007 Sep;64(9):1069-77. doi: 10.1001/archpsyc.64.9.1069. Arch Gen Psychiatry. 2007. PMID: 17768272 Clinical Trial.

9

Pharmacogenetically driven treatments for alcoholism: are we there yet?

Arias AJ, Sewell RA. Arias AJ, et al. CNS Drugs. 2012 Jun 1;26(6):461-76. doi: 10.2165/11633180-000000000-00000. CNS Drugs. 2012. PMID: 22587755 Free PMC article. Review.

10

Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues.

Schacht JP, Anton RF, Voronin KE, Randall PK, Li X, Henderson S, Myrick H. Schacht JP, et al. Neuropsychopharmacology. 2013 Feb;38(3):414-22. doi: 10.1038/npp.2012.195. Epub 2012 Oct 3. Neuropsychopharmacology. 2013. PMID: 23032071 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

95 results

Results by year